Saya, Hideyuki

写真a

Affiliation

School of Medicine (Mita)

Position

Professor Emeritus

External Links
Page Top ▲

Profile 【 Display / hide 】

  • Hideyuki Saya MD, PhD graduated from Kobe University School of Medicine in 1981 and was Resident in the Neurosurgery until 1983. After which he joined the Graduate School of Medical Sciences granting his PhD in 1987. He studied as a Postdoctoral Fellow in UCSF until 1988 then was appointed Assistant Professor at the Neuro-Oncology, M.D. Anderson Cancer Center. Houston, TX. From 1994 to 2006 he was Professor, Kumamoto University School of Medicine before taking his current position in Keio University School of Medicine in 2007. He is currently a vice president of Keio University Hospital and Director of Clinical and Translational Research Center.

Page Top ▲

Other Affiliation 【 Display / hide 】

  • School of Medicine, Professor

Page Top ▲
 

Papers 【 Display / hide 】

  • 2-Nitroimidazoles induce mitochondrial stress and ferroptosis in glioma stem cells residing in a hypoxic niche

    Koike N., Kota R., Naito Y., Hayakawa N., Matsuura T., Hishiki T., Onishi N., Fukada J., Suematsu M., Shigematsu N., Saya H., Sampetrean O.

    Communications Biology (Communications Biology)  3 ( 1 )  2020.12

    　View Summary

    © 2020, The Author(s). Under hypoxic conditions, nitroimidazoles can replace oxygen as electron acceptors, thereby enhancing the effects of radiation on malignant cells. These compounds also accumulate in hypoxic cells, where they can act as cytotoxins or imaging agents. However, whether these effects apply to cancer stem cells has not been sufficiently explored. Here we show that the 2-nitroimidazole doranidazole potentiates radiation-induced DNA damage in hypoxic glioma stem cells (GSCs) and confers a significant survival benefit in mice harboring GSC-derived tumors in radiotherapy settings. Furthermore, doranidazole and misonidazole, but not metronidazole, manifested radiation-independent cytotoxicity for hypoxic GSCs that was mediated by ferroptosis induced partially through blockade of mitochondrial complexes I and II and resultant metabolic alterations in oxidative stress responses. Doranidazole also limited the growth of GSC-derived subcutaneous tumors and that of tumors in orthotopic brain slices. Our results thus reveal the theranostic potential of 2-nitroimidazoles as ferroptosis inducers that enable targeting GSCs in their hypoxic niche.

  • Phosphorylation of the Anaphase Promoting Complex activator FZR1/CDH1 is required for Meiosis II entry in mouse male germ cell

    Tanno N., Kuninaka S., Fujimura S., Takemoto K., Okamura K., Takeda N., Araki K., Araki M., Saya H., Ishiguro K.i.

    Scientific Reports (Scientific Reports)  10 ( 1 )  2020.12

    　View Summary

    © 2020, The Author(s). FZR1/CDH1 is an activator of Anaphase promoting complex/Cyclosome (APC/C), best known for its role as E3 ubiquitin ligase that drives the cell cycle. APC/C activity is regulated by CDK-mediated phosphorylation of FZR1 during mitotic cell cycle. Although the critical role of FZR1 phosphorylation has been shown mainly in yeast and in vitro cell culture studies, its biological significance in mammalian tissues in vivo remained elusive. Here, we examined the in vivo role of FZR1 phosphorylation using a mouse model, in which non-phosphorylatable substitutions were introduced in the putative CDK-phosphorylation sites of FZR1. Although ablation of FZR1 phosphorylation did not show substantial consequences in mouse somatic tissues, it led to severe testicular defects resulting in male infertility. In the absence of FZR1 phosphorylation, male juvenile germ cells entered meiosis normally but failed to enter meiosis II or form differentiated spermatids. In aged testis, male mutant germ cells were overall abolished, showing Sertoli cell-only phenotype. In contrast, female mutants showed apparently normal progression of meiosis. The present study demonstrated that phosphorylation of FZR1 is required for temporal regulation of APC/C activity at meiosis II entry, and for maintenance of spermatogonia, which raised an insight into the sexual dimorphism of FZR1-regulation in germ cells.

  • Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma

    Shono K., Yamaguchi I., Mizobuchi Y., Kagusa H., Sumi A., Fujihara T., Nakajima K., Kitazato K.T., Matsuzaki K., Saya H., Takagi Y.

    Scientific Reports (Scientific Reports)  10 ( 1 )  2020.12

    　View Summary

    © 2020, The Author(s). Glioblastoma multiforme involves glioma stem cells (GSCs) that are resistant to various therapeutic approaches. Here, we studied the importance of paracrine signaling in the glioma microenvironment by focusing on the celecoxib-mediated role of chemokines C–C motif ligand 2 (CCL2), C-X-C ligand 10 (CXCL10), and their receptors, CCR2 and CXCR3, in GSCs and a GSC-bearing malignant glioma model. C57BL/6 mice were injected with orthotopic GSCs intracranially and divided into groups administered either 10 or 30 mg/kg celecoxib, or saline to examine the antitumor effects associated with chemokine expression. In GSCs, we analyzed cell viability and expression of chemokines and their receptors in the presence/absence of celecoxib. In the malignant glioma model, celecoxib exhibited antitumor effects in a dose dependent manner and decreased protein and mRNA levels of Ccl2 and CxcL10 and Cxcr3 but not of Ccr2. CCL2 and CXCL10 co-localized with Nestin+ stem cells, CD16+ or CD163+ macrophages and Iba-1+ microglia. In GSCs, celecoxib inhibited Ccl2 and Cxcr3 expression in a nuclear factor-kappa B-dependent manner but not Ccr2 and CxcL10. Moreover, Ccl2 silencing resulted in decreased GSC viability. These results suggest that celecoxib-mediated regulation of the CCL2/CCR2 and CXCL10/ CXCR3 axes may partially contribute to glioma-specific antitumor effects.

  • Molecular and cellular mechanisms underlying brain metastasis of breast cancer

    Hosonaga M., Saya H., Arima Y.

    Cancer and Metastasis Reviews (Cancer and Metastasis Reviews)  39 ( 3 ) 711 - 720 2020.09

    ISSN  01677659

    　View Summary

    © 2020, The Author(s). Metastasis of cancer cells to the brain occurs frequently in patients with certain subtypes of breast cancer. In particular, patients with HER2-positive or triple-negative breast cancer are at high risk for the development of brain metastases. Despite recent advances in the treatment of primary breast tumors, the prognosis of breast cancer patients with brain metastases remains poor. A better understanding of the molecular and cellular mechanisms underlying brain metastasis might be expected to lead to improvements in the overall survival rate for these patients. Recent studies have revealed complex interactions between metastatic cancer cells and their microenvironment in the brain. Such interactions result in the activation of various signaling pathways related to metastasis in both cancer cells and cells of the microenvironment including astrocytes and microglia. In this review, we focus on such interactions and on their role both in the metastatic process and as potential targets for therapeutic intervention.

  • Targeting of cancer stem cells by differentiation therapy

    Arima Y., Nobusue H., Saya H.

    Cancer Science (Cancer Science)  111 ( 8 ) 2689 - 2695 2020.08

    ISSN  13479032

    　View Summary

    © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Chemoresistance is a hallmark of cancer stem cells (CSCs). To develop novel therapeutic strategies that target CSCs, we established osteosarcoma-initiating (OSi) cells by introducing the c-Myc gene into bone marrow stromal cells derived from Ink4a/Arf KO mice. These OSi cells include bipotent committed cells (similar to osteochondral progenitor cells) with a high tumorigenic activity as well as tripotent cells (similar to mesenchymal stem cells) of low tumorigenicity. We recently showed that the tripotent OSi cells are highly resistant to chemotherapeutic agents, and that depolymerization of the actin cytoskeleton in these cells induces their terminal adipocyte differentiation and suppresses their tumorigenicity. We here provide an overview of modulation of actin cytoskeleton dynamics associated with terminal adipocyte differentiation in osteosarcoma as well as discuss the prospects for new therapeutic strategies that target chemoresistant CSCs by inducing their differentiation.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • メチオニン代謝を基盤としたがん治療抵抗性機構の解明と新規治療標的の同定

    2021.07
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory), Principal investigator

  • がん関連線維芽細胞誘導分子機構の解明とその阻害に基づく腫瘍微小環境制御

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A) , Principal investigator

  • 癌細胞シグナル活性化因子14-3-3ζを標的とした新規膵臓癌治療薬の開発

    2019.06
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Challenging Research (Exploratory) , Principal investigator

  • Elucidation of underlyingmechanism of MKL1-mediated induction of cancer associated fibroblasts and its clinical applications

    2017.04
    -
    2020.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A) , Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • MEDICAL PROFESSIONALISM 3

    2023

  • MEDICAL PROFESSIONALISM 3

    2022

  • MCB(MOLECULAR CELL BIOLOGY)

    2022

  • ADVANCED MEDICAL TECHNOLOGIES

    2022

  • ADVANCED MEDICAL RESEARCH

    2022

display all >>

Page Top ▲